ASOs targeting ARL4C (ASO-1316) showed decreased RAS-related substrate activity, inhibited cell proliferation and migration, and suppressed nuclear import of Yes-associated protein-1 (YAP-1) in lung cancer cell lines bearing KRAS and EGFR mutations. Here, EGFR is linked to lung cancer.